Tenaya Therapeutics (TNYA) Leases (2021 - 2026)

Tenaya Therapeutics has reported Leases for 6 years, with the latest figure at $8.8 million in Q1 2026.

• For the quarter ending Q1 2026, Leases fell 22.41% year-over-year to $8.8 million; the trailing twelve-month figure through Mar 2026 stood at $8.8 million (down 22.41% YoY), and the FY2025 full-year result was $9.4 million, down 20.8% from the prior year.
• Leases for Q1 2026 stood at $8.8 million, down from $9.4 million in the prior quarter.
• The five-year high for Leases was $13.7 million in Q2 2024, with the low at $8.8 million in Q1 2026.
• Average Leases over 5 years is $11.0 million, with a median of $10.9 million recorded in 2023.
• Year-over-year, Leases declined 24.7% in 2023 and jumped 35.23% in 2024.
• Tracing TNYA's Leases over 5 years: stood at $11.7 million in 2022, then decreased by 14.44% to $10.0 million in 2023, then gained by 19.15% to $11.9 million in 2024, then decreased by 20.8% to $9.4 million in 2025, then dropped by 6.94% to $8.8 million in 2026.
• The last three Leases figures came in at $8.8 million (Q1 2026), $9.4 million (Q4 2025), and $10.1 million (Q3 2025), per Business Quant data.

Peer Comparison